Nacuity Pharmaceuticals and Arctic Therapeutics Enter Licensing Agreement and Strategic Partnership to Develop NPI-001
Collaboration leverages Nacuity’s NPI-001 for the treatment of fatal rare disease HCCAA in Iceland FORT…
Year: 2022
Nacuity Pharmaceuticals and Arctic Therapeutics Enter Licensing Agreement and Strategic Partnership to Develop NPI-001
Collaboration leverages Nacuity’s NPI-001 for the treatment of fatal rare disease HCCAA in Iceland FORT…
Eton Pharmaceuticals Announces Acquisition of FDA-Approved Rare Disease Product, Betaine Anhydrous for Oral Solution
— Expected to be accretive to 2023 earnings — DEER PARK, Ill., Sept. 13, 2022…
Eton Pharmaceuticals Announces Acquisition of FDA-Approved Rare Disease Product, Betaine Anhydrous for Oral Solution
— Expected to be accretive to 2023 earnings — DEER PARK, Ill., Sept. 13, 2022…
Altamira Therapeutics Completes Enrollment for COVAMID Trial with Bentrio in Acute COVID-19
HAMILTON, BERMUDA , Sept. 13, 2022 (GLOBE NEWSWIRE) — Study has reached extended enrollment target…
Altamira Therapeutics Completes Enrollment for COVAMID Trial with Bentrio in Acute COVID-19
HAMILTON, BERMUDA , Sept. 13, 2022 (GLOBE NEWSWIRE) — Study has reached extended enrollment target…
BrightInsight Launches the BrightInsight Ecosystem Bringing Together Leading Healthcare and Technology Companies to Revolutionize Patient Care Through Digital
Leaders From All Facets of Healthcare Will Collaborate to Drive Digital Innovation and Adoption BrightInsight…
BrightInsight Launches the BrightInsight Ecosystem Bringing Together Leading Healthcare and Technology Companies to Revolutionize Patient Care Through Digital
Leaders From All Facets of Healthcare Will Collaborate to Drive Digital Innovation and Adoption BrightInsight…
Neuronetics, Inc. Announces Grand Opening of NeuroStar® University with Ribbon-Cutting Ceremony
The state-of-the-art training center is the first of its kind to further best practices with…
Neuronetics, Inc. Announces Grand Opening of NeuroStar® University with Ribbon-Cutting Ceremony
The state-of-the-art training center is the first of its kind to further best practices with…
Quoin Pharmaceuticals Establishes Patient Specific Website for Ongoing Netherton Syndrome Clinical Study
Three clinical sites are now fully open; final three sites expected to open imminently ASHBURN,…
Quoin Pharmaceuticals Establishes Patient Specific Website for Ongoing Netherton Syndrome Clinical Study
Three clinical sites are now fully open; final three sites expected to open imminently ASHBURN,…
Nuvectis Pharma Announces Positive Data for NXP800 in a Preclinical Model of ARID1a-Mutated Gastric Carcinoma
ARID1a- mutated gastric carcinoma model (SNU-1) Tumor volumes over time FORT LEE, N.J., Sept. 13,…
Nuvectis Pharma Announces Positive Data for NXP800 in a Preclinical Model of ARID1a-Mutated Gastric Carcinoma
ARID1a- mutated gastric carcinoma model (SNU-1) Tumor volumes over time FORT LEE, N.J., Sept. 13,…
ABVC Biopharma Announces Letter to Shareholders
FREMONT, CA, Sept. 13, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — ABVC BioPharma, Inc. (Nasdaq:…
ABVC Biopharma Announces Letter to Shareholders
FREMONT, CA, Sept. 13, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — ABVC BioPharma, Inc. (Nasdaq:…
Biofrontera Inc. Names Gerard DiGirolamo as National Sales Director
WOBURN, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) — Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company…
Biofrontera Inc. Names Gerard DiGirolamo as National Sales Director
WOBURN, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) — Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company…
Novome Biotechnologies Raises $43.5 Million Series B Financing to Advance its Pipeline of Therapeutically Engineered Microbes
– Funding supports ongoing Phase 2a clinical trial in patients with enteric hyperoxaluria, and pipeline…
Novome Biotechnologies Raises $43.5 Million Series B Financing to Advance its Pipeline of Therapeutically Engineered Microbes
– Funding supports ongoing Phase 2a clinical trial in patients with enteric hyperoxaluria, and pipeline…